2025-04-18 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis

**0. Executive Summary:**

Johnson & Johnson (JNJ), a multinational pharmaceutical and consumer goods company, shows a cumulative return significantly lagging behind the S&P 500 (VOO) over the observed period. While exhibiting periods of positive alpha, recent performance has been weak, marked by negative CAGR and a relatively low RSI.  Further analysis is needed to determine if this underperformance is temporary or indicative of a larger trend.


**1. Performance Comparison:**

Johnson & Johnson (JNJ) is a diversified healthcare company producing pharmaceuticals, medical devices, and consumer goods.

* **Cumulative Return (JNJ):** 39.81%
* **Cumulative Return (VOO):** 76.18%
* **Return Difference:** -36.4%  (JNJ underperformed VOO by 36.4%)
* **Relative Divergence:** 41.4% (This indicates JNJ's current underperformance relative to VOO is in the lower 41.4% percentile of historical divergences observed between the two)


**Alpha and Beta Analysis:**

The provided data shows fluctuating alpha and beta values over the years.  While periods of positive alpha (outperformance relative to the market) exist, recent years show negative CAGR and consistently lower alpha, indicating underperformance against the market benchmark.  The market capitalization (Cap(B)) has generally increased, but the negative CAGR in recent years is noteworthy.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 33.0% | 55.5% | 1.0% | 0.1 | 275.3 |
| 2016-2018  | 15.0% | 10.7% | -6.0% | -0.0 | 261.2 |
| 2017-2019  | 25.0% | 10.7% | -8.0% | 0.7 | 303.6 |
| 2018-2020  | 20.0% | 59.4% | -10.0% | 0.5 | 336.4 |
| 2019-2021  | 36.0% | 59.5% | -25.0% | 0.4 | 374.9 |
| 2020-2022  | 8.0% | 61.3% | -1.0% | 0.3 | 397.3 |
| 2021-2023  | -17.0% | 61.3% | -38.0% | 0.4 | 363.2 |
| 2022-2024  | -31.0% | 61.3% | -51.0% | 0.3 | 345.7 |
| 2023-2025  | 1.0% | 69.7% | -13.0% | 0.1 | 379.5 |


**2. Recent Price Movement:**

* **Closing Price:** $157.47
* **5-Day Moving Average:** $154.22
* **20-Day Moving Average:** $156.77
* **60-Day Moving Average:** $157.93

The price is slightly below the 60-day moving average, suggesting potential for further price correction or consolidation.  The recent price increase (Last-market data) shows a positive change of 2.31, indicative of a short-term upward movement.


**3. Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.4223 (Medium Risk)
* **RSI:** 43.01 (Approaching oversold territory, but not yet definitively so)
* **PPO:** 0.036 (Slightly positive, suggesting potential for further upward momentum, but weak)
* **20-Day Relative Divergence Change:** +3.7 (Short-term upward trend)
* **Expected Return (vs. S&P 500, long-term):** -37.0% (This suggests significant underperformance relative to the S&P 500 over the long term, based on current projections)

The recent price increase ('Last-market' data showing a positive 'change') does not indicate a sharp upward surge (no '급반등').



**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue       |
|------------|--------|----------------|
| 2024-10-23 | 1.12   | $22.47 B      |
| 2024-07-25 | 1.95   | $22.45 B      |
| 2024-05-01 | 1.35   | $21.38 B      |
| 2024-02-16 | 1.68   | $21.39 B      |
| 2023-10-27 | 10.32  | $21.35 B      |

EPS shows significant volatility, with a particularly high EPS in October 2023. Revenue remains relatively stable but lacks significant growth.  Further investigation into the reasons for the EPS volatility is needed.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue      | Profit Margin |
|---------|--------------|---------------|
| 2024-12-31 | $22.52B     | 68.35%        |
| 2024-09-30 | $22.47B     | 69.01%        |
| 2024-06-30 | $22.45B     | 69.40%        |
| 2024-03-31 | $21.38B     | 69.55%        |
| 2023-12-31 | $21.39B     | 68.23%        |

Revenue is relatively stable, and profit margins are consistently high.


**Capital and Profitability:**

| Quarter | Equity       | ROE     |
|---------|--------------|---------|
| 2024-12-31 | $71.49B     | 4.80%  |
| 2024-09-30 | $70.16B     | 3.84%  |
| 2024-06-30 | $71.54B     | 6.55%  |
| 2024-03-31 | $70.02B     | 4.65%  |
| 2023-12-31 | $68.77B     | 5.89%  |

Equity and ROE show some fluctuation, but generally remain at a healthy level.



**6. Overall Analysis:**

JNJ's recent performance has lagged behind the S&P 500, exhibiting negative CAGR and lower alpha in recent years. While the company demonstrates strong and stable revenue and profit margins, the fluctuating EPS and the significant projected long-term underperformance against the S&P 500 raise concerns. The technical indicators suggest a potential for further price consolidation or correction.  Further investigation is warranted to understand the reasons for the recent underperformance, including factors such as industry trends, competitive pressures, and potential regulatory changes.  A thorough assessment of the long-term growth prospects is crucial before making any investment decisions.  The negative expected return of -37% compared to the S&P 500 over the long term is a significant negative.
